Updated Jul 17, 2026
Weis Holger has filed 5 SEC Form 4 filings across 2 companies in the last 90 days.
Holger Weis is the Chief Executive Officer of Alaunos Therapeutics, Inc., a company focused on developing drugs for obesity and metabolic health. He has been involved in the company's operations as it works on its primary program, ALN1001.
| Role | Director |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-13 | JUNS | JUPITER NEUROSCIENCES, INC. | M — Option exercise | 85.8K | — | |
| 2026-07-02 | TCRT | Alaunos Therapeutics, Inc. | A — Grant or award | 3.9K | $2.26 | $9K |
| 2026-06-17 | TCRT | Alaunos Therapeutics, Inc. | A — Grant or award | 7.8K | $2.26 | $18K |
| 2026-05-27 | TCRT | Alaunos Therapeutics, Inc. | A — Grant or award | 3.7K | $2.37 | $9K |
Holger Weis is the Chief Executive Officer of Alaunos Therapeutics, Inc., a company focused on developing drugs for obesity and metabolic health. He has been involved in the company's operations as it works on its primary program, ALN1001.…
5 primary Form 4 filings in the last 90 days, covering 2 companies.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Weis Holger profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.